Lenire is an evidence-based tinnitus treatment developed and released in the UK by Neuromod in 2015. It is a non-invasive at-home medical device treatment method for chronic and persistent tinnitus (ringing in the ears). A clinician must prescribe Lenire, and treatment requires monitoring over a three-month time period as adjustments may be needed to optimize device effectiveness. A standard course of Lenire treatment lasts for 30 minutes and is used daily.
A clinical trial of Lenire was conducted at the St James’s Hospital in Dublin and the Tinnituszentrum of the University Regensburg, Germany, from 2016-2019 and had 326 participants. The study results showed that approximately 86% of treatment-compliant patients reported tinnitus symptom improvement over a 12-week period, and approximately 80% of treatment-compliant patients reported improvement over a 12-month time period.